All News
Dr. Alberta Hoi graphically presents the difference bet acute confusional states & chronic cognitive changes in #lupus patients presenting with NP symptoms.
NPSLE continues to pose a diagnostic challenge bec pts may present with more than one syndrome complex
@RheumNow #APLAR25 https://t.co/4nYTo1fzVz
sheila RHEUMarampa ( View Tweet)
How to treat CTD ILD?
A comparative slide summarizing ACR/BSR and EULAR treatment guidelines
Emphasis on combination of Immunosuppressant and Antifibrotics
@RheumNow #APLAR25 https://t.co/gLSht6QKh5
Aurelie Najm AurelieRheumo ( View Tweet)
“Listen to the patient, he is telling you the diagnosis”. – Sir William Osler
Dr. John Cush RheumNow ( View Tweet)
A framework for treatment stratified approach in CTD-ILD, by Dr Low Hsiu Ling
Based on
-ILD extent
-Risk of progression
-Biology: fibrosis/inflammation
-Safety
-Other manifestations
@RheumNow #APLAR25 https://t.co/ma5KugzBHy
Aurelie Najm AurelieRheumo ( View Tweet)
‼️More reasons why we should avoid steroids in #lupus patients
@RheumNow #APLAR25 https://t.co/a5IeutJ5mi
Links:
sheila RHEUMarampa ( View Tweet)
Why shall we screen all patients with SSc for ILD?
Focusing screening strategy on patients « at risk » misses 25% of patients with ILD
ILD being the main cause of mortality in SSc
@RheumNow #APLAR25 https://t.co/djzCTdZoVb
Aurelie Najm AurelieRheumo ( View Tweet)
The overall prevalence of #osteoporosis in SLE is ~33-40% and is due to several factors with GC therapy being one of them.
Monitor DXA every 6-12 months (vs. 2 yrs for standard OP)
☝️Screen for GIOP
☝️Treat accordingly - once on GCs & esp w/long-term use
@RheumNow #APLAR25 https://t.co/E9FJDHrBUo
Links:
sheila RHEUMarampa ( View Tweet)
Paradigm shift in CTD PAH
-Early triple therapy in patients with intermediate and high risk
-Sotatercept,
a blocker of activin-Smad2/3 signaling
have increased survival importantly
Data presented by Dr Khanna
@RheumNow #APLAR25 https://t.co/Z4yA6DwtOb
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
An important message from Prof. @XBaraliakos on D2M-axSpA:
Re-evaluate your diagnosis & check for comorbids before labelling pts as tx-refractory or difficult-to-manage.
consider other causes: FM, other causes of pain
@RheumNow #APLAR25 @rheumarhyme @marklagacmd https://t.co/Lo0yShOK0P
Links:
sheila RHEUMarampa ( View Tweet)
Drivers of costs associated with economic costs of RMDs in Asia Pacific
-Traditional medicine
-Loss of income much higher if worker as opposed to unpaid household labor so high impact of gender roles
-Impact of out of pocket health payments due to « catastrophic spendings » in https://t.co/sptwGE7J2V
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
Prof. Aletaha shares their AutoPiX project - using AI to develop quantitative biomarkers.
Something to look forward to since imaging remains an important diagnostic tool in #rheumatology
@RheumNow #APLAR25 @rheumarhyme https://t.co/WExT9amazz
Links:
sheila RHEUMarampa ( View Tweet)
Update on Rheumatology workforce shortage in Asia-Pacific
Date presented by Dr Ahmad
Number of Rheumatologists per 100000 inhabitants across @APLAR_org countries
-3 in Japan
-1.3 in Australia, Hong Kong, Singapore
-0.03 in Pakistan
As a result: delayed diagnosis for patients! https://t.co/Hycqtp8BtY
Aurelie Najm AurelieRheumo ( View Tweet)
Peter Taylor on extra articular manifestations of RA
Keep an eye on RA patients’ glomerular function
RA patients have increased risk of CKD
Systematic review >1million pts
Risk Ratio 1.52
@RheumNow #APLAR25 https://t.co/5iZwtmvwSR
Aurelie Najm AurelieRheumo ( View Tweet)
Hyperferritinemia is common in Hyperinflammatory syndromes but is a hallmark of Macrophage activation syndrome and Sepsis; and is a poor prognostic sign too. MAS is excessive activation of T-lymphocytes & macrophages leading to cytokine storm & multi-organ damage. https://t.co/MUKXC0Tw3M
Dr. John Cush RheumNow ( View Tweet)
🆕 Intro to ILD (Part I): the essentials
🫁 Definition & basics
🔬 Key pathology patterns
🧑⚕️ Clinical approach
📋 What rheums need to know
⬇️ Download & learn more: https://t.co/7RzpTDOjwa
Created by @MithuRheum | via @RheumNow for our Rheum to Breathe: ILD Campaign https://t.co/D9d97bqcD5
Dr. John Cush RheumNow ( View Tweet)
💥 New week, new quiz.
Take 90 seconds. Prove you're the rheum news MVP.
📈 Track your accuracy
🏁 Race to the top of the leaderboard
🎯 Review what you missed
Take the RheumIQ quiz ➡️ https://t.co/CASRQjoYrB https://t.co/FCjkqud0y4
Links:
Dr. John Cush RheumNow ( View Tweet)
Lessons Learned in Neuropsychiatric SLE
Dr. Sheila Reyes, The Philippines, reports highlights from a session on neuropsychiatric systemic lupus erythematosus, presented at the APLAR 2025 Congress in Fukuoka, Japan.
https://t.co/Dh1GQnBhvg https://t.co/wX5FgpIq7C
Dr. John Cush RheumNow ( View Tweet)
PAH diagnosis and management in the context of CTD ILD
Pulmonary arterial hypertension (PAH) is a serious complication of connective tissue disorders (CTD), affecting about 25% of PAH patients. CTD-PAH is the second most common cause after the idiopathic form. PAH involves high https://t.co/UgsdYWv02S
Dr. John Cush RheumNow ( View Tweet)
QD Clinic Video: RA and Bronchiectasis
Dr. Jeffrey Sparks, Boston, talks about rheumatoid arthritis and bronchiectasis as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025.
https://t.co/Y2u3m4rFfj https://t.co/KgrIxXlQo4
Dr. John Cush RheumNow ( View Tweet)
STOP-RA results published in A&R. 144 at risk, CCP+ pts were enrolled to received HCQ vs PBO for 12 mos, w/ 24 mos F/U. Progression to RA seen in 30.4% on HCQ vs 32.9% on PBO (NS; P=0.52). Also IA, Jt Sxs, severity & adverse events were similar between groups.
Dr. John Cush RheumNow ( View Tweet)
